Skip to content
Screener

Supernus Pharmaceuticals SUPN APOKYN — Total revenues

Other product segments

Qelbree
$77.84M+20.2%
GOCOVRI
$35.24M+14.8%
Royalty, licensing, and other revenues
$29.31M+274%
Collaboration revenue (ZURZUVAE)
$27.64M—
Trokendi XR
$9.48M-26.0%
ONAPGO
$8.38M—
Oxtellar XR
$7.42M-27.2%
Other
$4.67M-45.6%

Similar metrics at other companies

Sonida Senior Living logo
SNDAResident revenue — Total revenues
$108.43M+36.8%
Asset Entities logo
ASSTOther revenue — Total revenues
$43K+514%
ALN
ALNYRoyalty revenue — Total revenues
$71.67M+79.3%
Hyatt Hotels logo
HContra revenue — Total revenues
-$17M-13.3%
FTAI Aviation Ltd. logo
FTAIMaintenance revenue — Total revenues
$30.6M-38.3%
FTAI Aviation Ltd. logo
FTAIOther revenue — Total revenues
$6.21M+19,923%

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.72B+14.3%
Enterprise value$2.57B+13.6%
P/S3.5×-0.1×

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0×0.0×
Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001356576-26-000022
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
GOCOVRI35,24030,689
Trokendi XR9,47912,801
ONAPGO8,375—
APOKYN7,72814,976
Oxtellar XR7,42210,198
Other(1)4,6668,579
Total net product sales150,753141,988
Collaboration revenue (ZURZUVAE)(2)27,643—

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is Supernus Pharmaceuticals's APOKYN — total revenues?
Supernus Pharmaceuticals (SUPN) reported APOKYN — total revenues of $7.73M in Q1 2026.
How has Supernus Pharmaceuticals's APOKYN — total revenues changed year-over-year?
Supernus Pharmaceuticals's APOKYN — total revenues decreased by 48.4% year-over-year, from $14.98M to $7.73M.
What is the long-term trend for Supernus Pharmaceuticals's APOKYN — total revenues?
Over 4 years (2021 to 2025), Supernus Pharmaceuticals's APOKYN — total revenues has grown at a -16.7% compound annual growth rate (CAGR), from $99.23M to $47.77M.
What does APOKYN — total revenues mean?
This metric represents the total gross revenue generated from the sale of a specific pharmaceutical product or therapeutic line within the company's neuroscience portfolio. It serves as a key indicator of the product's market adoption, commercial performance, and contribution to the overall top-line growth of the organization. Tracking this revenue stream helps investors evaluate the lifecycle stage and competitive positioning of the specific treatment.

Ask your AI about Supernus Pharmaceuticals's apokyn — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude